FI930206L - Adoptiv immunoterapi med interleukin-7 - Google Patents

Adoptiv immunoterapi med interleukin-7 Download PDF

Info

Publication number
FI930206L
FI930206L FI930206A FI930206A FI930206L FI 930206 L FI930206 L FI 930206L FI 930206 A FI930206 A FI 930206A FI 930206 A FI930206 A FI 930206A FI 930206 L FI930206 L FI 930206L
Authority
FI
Finland
Prior art keywords
adoptiv
immunotherapy
interleukin
med
med interleukin
Prior art date
Application number
FI930206A
Other languages
English (en)
Other versions
FI930206A0 (fi
FI105045B (fi
Inventor
David H Lynch
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI930206A0 publication Critical patent/FI930206A0/fi
Publication of FI930206L publication Critical patent/FI930206L/fi
Application granted granted Critical
Publication of FI105045B publication Critical patent/FI105045B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
FI930206A 1990-07-26 1993-01-19 Menetelmä sytolyyttisten T-lymfosyyttien muodostamiseksi FI105045B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55900190 1990-07-26
US07/559,001 US5229115A (en) 1990-07-26 1990-07-26 Adoptive immunotherapy with interleukin-7
PCT/US1991/004919 WO1992001459A1 (en) 1990-07-26 1991-07-12 Adoptive immunotherapy with interleukin-7
US9104919 1991-07-12

Publications (3)

Publication Number Publication Date
FI930206A0 FI930206A0 (fi) 1993-01-19
FI930206L true FI930206L (fi) 1993-01-19
FI105045B FI105045B (fi) 2000-05-31

Family

ID=24231881

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930206A FI105045B (fi) 1990-07-26 1993-01-19 Menetelmä sytolyyttisten T-lymfosyyttien muodostamiseksi

Country Status (16)

Country Link
US (1) US5229115A (fi)
EP (1) EP0540599B1 (fi)
JP (1) JP3825467B2 (fi)
AT (1) ATE161180T1 (fi)
AU (1) AU646881B2 (fi)
CA (1) CA2087525C (fi)
DE (1) DE69128476T2 (fi)
DK (1) DK0540599T3 (fi)
ES (1) ES2112860T3 (fi)
FI (1) FI105045B (fi)
GR (1) GR3026358T3 (fi)
IE (1) IE912486A1 (fi)
IL (1) IL98957A (fi)
NO (1) NO930243L (fi)
NZ (1) NZ239113A (fi)
WO (1) WO1992001459A1 (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
EP0705104A4 (en) * 1993-03-02 1997-06-18 David S Terman ANTI-CANCER THERAPY
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
CN1237909A (zh) * 1996-10-11 1999-12-08 加利福尼亚大学董事会 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2848255B1 (en) 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
WO2003044183A1 (en) * 2001-11-22 2003-05-30 Medigenes Interleukin-2 gene transferred lymphokine activated killer cells
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
ES2542141T3 (es) 2005-10-17 2015-07-31 Sloan Kettering Institute For Cancer Research Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
EP2374813A1 (en) 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Use of phenol-soluble modulins for vaccine development
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP3628322A1 (en) 2013-03-01 2020-04-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
EP4324477A3 (en) 2016-12-08 2024-05-22 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2019241536A1 (en) * 2018-06-14 2019-12-19 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4902288A (en) * 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
AU3183089A (en) * 1988-02-11 1989-09-06 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Also Published As

Publication number Publication date
DK0540599T3 (da) 1998-08-24
NO930243D0 (no) 1993-01-25
EP0540599B1 (en) 1997-12-17
FI930206A0 (fi) 1993-01-19
ES2112860T3 (es) 1998-04-16
IE912486A1 (en) 1992-01-29
NO930243L (no) 1993-01-25
ATE161180T1 (de) 1998-01-15
WO1992001459A1 (en) 1992-02-06
DE69128476T2 (de) 1998-07-23
IL98957A0 (en) 1992-07-15
AU8287291A (en) 1992-02-18
EP0540599A1 (en) 1993-05-12
AU646881B2 (en) 1994-03-10
JPH05509093A (ja) 1993-12-16
GR3026358T3 (en) 1998-06-30
DE69128476D1 (de) 1998-01-29
IL98957A (en) 2000-11-21
US5229115A (en) 1993-07-20
JP3825467B2 (ja) 2006-09-27
FI105045B (fi) 2000-05-31
NZ239113A (en) 1997-07-27
CA2087525C (en) 2006-05-30
CA2087525A1 (en) 1992-01-27

Similar Documents

Publication Publication Date Title
FI930206L (fi) Adoptiv immunoterapi med interleukin-7
FI925177L (fi) Ventilsystem med en loestagbar fluidgraensyta
FI932535A7 (fi) Tryckoeverfoerare med en djupning foer spaenningsisolering
FI931962L (fi) Fibrigt superabsorberande innerstycke med integrerat faest hydrofobt yttre skikt
FI932844L (fi) Sanitetsbinda med vertikalt segmenterad kaerna
FI932669A0 (fi) Flerpoligt skaermat kontaktdon med gemensam jord
FI930911L (fi) Omslagsbaerfodral foersedd med artikelhaollare
FI931949A7 (fi) Luftfjaeder med snabbutloesning
FI922193L (fi) Expansionspropp med friktionsminskande beskiktning
FI922162A7 (fi) Doerrstaengningsanordning med laosningsmekanism foer hissar
FI921840L (fi) Monoalkylfosfinat- och monoalkylfosfonatsampolymerer med laog molekylvikt
FI922226L (fi) Elektrostatisk hoegspaenningsmaolfaergssprutpistol med laogt tryck
FI920718L (fi) Vaetskefoerdelare med indraget foerdelningsmunstycke
FI930606L (fi) Moppoeverdrag med styranordning foer faestet
FI931713L (fi) Med vattenhaltigt expansionsmedel framstaellt sulfonpolymerskum
FI924837L (fi) Omslagsbaerfodral foersett med reglerbara flaskhalsoeppningar
FI924815L (fi) Omriktare med stroembegraensning
FI923898A7 (fi) Kortslutnings- och borstupplyftningsanordning foer asynkronmotorer med slaepringsrotor
FI920971L (fi) Slangformigt livsmedelshoelje med foerbaettrad avskalning
FI922144A7 (fi) Baeranordning med upprivbara bandsegment
FI930268A7 (fi) Anordning foer belysning med polariserat ljus
FI932453L (fi) Geltypkompositioner med foerbaettrad fettkontroll
FI930560L (fi) Naetdriven med fasskaerningskontroll utrustad koppling
FI920734L (fi) Ketosyror innehaollande kinoliner med leukotrienantagonisteffekt
FI920970L (fi) Slangformigt livsmedelshoelje med foerbaettrad avskalning

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: SANOFI

MA Patent expired